

JOEL DAVID KALLICH

CONTACT INFORMATION

Big Health Data
43 Applewood Lane
Falmouth, Maine 04105
www.bighhealthdata.net

Analytics & Consulting
Phone: 207-805-1833
Cell: 818-651-3849
Email: jkallich@bighealthdata.net

EDUCATION

1990	Ph.D.	Sociology	Boston University
1978	M.A.	Sociology	University of Iowa
1976	B.G.S.	Interdisciplinary	University of Iowa

Dissertation Previous Health Care Utilization as a Predictor of Enrollment in Managed Care by Families Eligible for Medicaid

PROFESSIONAL EXPERIENCE

2013-Present	<i>Principal, Big Health Data, Falmouth, Maine</i>
1995-2013	<i>Amgen Inc., Thousand Oaks, California</i>
2011-2013	<i>Director, Observational Research, Center for Observational Research</i>
2008-2010	<i>Director, General Medicine Therapeutic Area Global Health Economics Lead</i>
1999-2008	<i>Director, Aranesp Oncology Global Health Economics and Global Payer Lead</i>
1995-1999	<i>Senior Manager, Health Economics & Epidemiology, Clinical Research</i>
1994-1995	<i>Principal, Health Policy Analysis, West Hills, California</i>
1990-1994	<i>Senior Social Scientist, RAND Corporation, Santa Monica, California</i>
1989-1990	<i>Senior Program Analyst, Office of Inspector General, US Department of Health and Human Services, Boston, Massachusetts</i>
1986-1989	<i>Director Policy Analysis, Medicaid, Massachusetts Department of Public Welfare, Boston, Massachusetts</i>
1983-1986	<i>Manager, Maternal and Child Health Statistics, Massachusetts Department of Public Health, Boston, Massachusetts</i>

TEACHING EXPERIENCE

2009	<i>Adjunct Professor, Quantitative Decision Making, California State University Northridge, Northridge, California</i>
2005-2008	<i>Adjunct Professor, General Internal Medicine, University of California Los Angeles, Los Angeles, California</i>
1982	<i>Instructor, Medical Sociology, Northeastern University, Boston, Massachusetts</i>
1981	<i>Instructor, Principles of Sociology, Boston Metropolitan College, Boston, Massachusetts</i>
1979-1980	<i>Teaching Fellow, Medical Sociology & Sociology of Sport, Boston University, Boston, Massachusetts</i>

GRANTS AND CONTRACTS (AWARDED)

2014	<i>Consultant</i> , Flatiron Health, Inc.
2013-2014	<i>Consultant</i> , Strategic Services, IMS Health, Inc.
2013-2014	<i>Consultant</i> , Leukemia & Lymphoma Society
1995-1996	<i>Principal Investigator</i> , Evaluation of Solid Organ Transplantation Services In New Jersey, New Jersey Department of Health and Senior Services
1994-1995	<i>Principal Investigator</i> , Design of a Cost-Effectiveness Protocol for the Mortality and Morbidity in Hemodialysis Clinical Trial, Health Care Financing Administration
1993-1994	<i>Co-Principal Investigator</i> , Development of an ESRD Specific Health Related Quality of Life Instrument, University of Arizona and Amgen Inc.
1992-1993	<i>Co-Principal Investigator</i> , Evaluation of a Capitation Payment for ESRD Services, Health Care Financing Administration
1991-1992	<i>Principal Investigator</i> , Rates of Transplantation for ESRD Beneficiaries, Health Care Financing Administration
1991-1992	<i>Principal Investigator</i> , Rates of Inpatient and Outpatient Shunt Related Services to ESRD Beneficiaries, Health Care Financing Administration
1991-1993	<i>Principal Investigator</i> , Center Billings for Ancillary Dialysis Services, Health Care Financing Administration
1990-1992	<i>Principal Investigator</i> , Access to Kidney Transplantation, Assistant Secretary for Planning and Evaluation and Health Care Financing Administration
1990-1991	<i>Project Director</i> , Evaluation of Pregnancy Outcomes, Agency for Health Care Policy and Research
1984-1986	<i>Survey Director</i> , Socio-Cultural Factors and Access to Prenatal Care for Low-Income Women, Public Health Service, Department of Health and Human Services

HONORS AND AWARDS

2007 & 2008	<i>Impact Award</i> , Amgen
1998	<i>Quality of Life Award</i> , Amgen
1991	<i>Inspection of the Year</i> , Office of the Inspector General, Department of Health and Human Services
1985	<i>Citation for Outstanding Performance</i> , Commonwealth of Massachusetts
1982	<i>Research Award</i> , Boston University Graduate School
1979-1982	<i>Scholarship</i> , Boston University Graduate School
1976-1978	<i>Scholarship</i> , University of Iowa

PROFESSIONAL ORGANIZATIONS

American Society of Clinical Oncology
 International Society for Pharmacoeconomics and Outcomes Research

PROFESSIONAL ACTIVITIES

2014	Leukemia & Lymphoma Society, The Economics of Innovation Workgroup Meeting
2013	National Cancer Institute, National Institutes of Health, National Coordinating Council for Cancer Surveillance
2012	National Comprehensive Cancer Network (NCCN) Data Needs Work Group, NCCN Oncology Policy Summit on Data Needs
2009-2010	Adjunct Professor, California State University Northridge
2005-2008	Adjunct Associate Professor, University of California Los Angeles, David Geffen School of Medicine
2006	Faculty, FDA Guidance on Patient Reported Outcomes: Discussion, Dissemination, and Operationalization, Mayo Clinic College of Medicine and FDA Center for Drug Evaluation and Research
2006-present	Reviewer, <i>Journal of General Internal Medicine</i>

1994-present	Reviewer, <i>Kidney International</i>
1994-present	Reviewer, <i>Quality of Life Research</i>
1990-present	Reviewer, <i>Medical Care</i>
2003-2004	International Society of Quality of Life Research, Program Committee
1997-1998	Member Expert Panel for Organ Donation, Agency for Health Care Policy and Research
1994	Member Review Panel for Managed Care Research Studies, Health Care Financing Administration
1992	Member Review Panel for Policy Implications of the National Cooperative Transplant Study, Northwestern University
1991	Member Review Panel for End Stage Renal Disease Research Studies, Health Care Financing Administration
1990	Reviewer, U.S. Congress, Office of Technology Assessment

PUBLICATIONS

Peer Reviewed Articles

- Smith, P., Byekwaso, S., Eremina, D., Kossar, B., Zhou, L., Quach, D., Quigley, J., Liede, A., Kallich, J., Adams, J., Projection Methods Using Oncology Electronic Health Records to Produce Nationally Representative Estimates, under review *Medical Care*.
- Paoli, C., Bach, B., Wong, B., Quach, D., Kallich, J., Performance Status of Real-world Oncology Patients Before and After 1st Course of Chemotherapy. Forthcoming, *Community Oncology*.
- Curtis, J., Cai, Q., Wade, S., Stolshek, B., Adams, A., Balasubramanian, A., Viswanathan, H., White, J., Kallich, J., Osteoporosis Medication Adherence: Physician's Perception Versus Results Based on Pharmacy Data From a U.S. Health Plan. *Bone*, 55:1-6, 2013.
- Whyte, J.L., Engel-Nitz, N., Teitelbaum, A., Gomez Rey, G., Kallich J., An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data. *Medical Care*, Epub ahead of print, Mar 21, 2013.
- Ward, M., Xu, Y., Viswanathan, H., Adams, J., Stolshek, B., Kallich, J., Saag, K., Association Between Osteoporosis Treatment Change and Adherence, Incident Fracture, and Total Healthcare Costs in a Medicare Advantage Prescription Drug Plan, *Osteoporosis International*, 24:1195-206, 2013.
- Chastek, B., Harley, C., Kallich, J., Newcomer, L., Paoli, C., Teitelbaum, A., Costs and utilization of oncology health services at the end of life. *Journal of Oncology Practice*, 8: 75s-80s, 2012.
- Nordstrom, B., Whyte, J., Stolar, M., Mercaldi, C., Kallich, J., Identification of Metastatic Cancer in Claims Data. *Pharmacoepidemiology and Drug Safety*, 21:S21-28, 2012.
- Wade, S., Curtis, J., Yu, J., White, J., Stolshek, B., Merinar, C., Balasubramanian, A., Kallich, J., Adams, J., Viswanathan, H., Medication adherence and fracture risk among patients on osteoporosis medications in a large United States health plan. *Bone*, 50:870-875, 2012.
- Viswanathan, H., Curtis, J., Yu, J., White, J., Stolshek, B., Merinar, C., Balasubramanian, A., Kallich, J., Adams, J., Wade, S., Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacologic osteoporosis therapy. *Applied Health Economics and Health Policy*, 10:163-173, 2012.
- Xu, Y., Viswanathan, H., Ward, M., Clay, B., Adams, J., Stolshek, B., Kallich, J., Fine, S., Saag, K., Patterns of Osteoporosis Treatment Change and Treatment Discontinuation among Commercial and Medicare Advantage Prescription Drug (MAPD) Members in a National Health Plan. *Journal of Evaluation in Clinical Practice*, 19:50-59, 2013.
- Xu, Y., Viswanathan, H., Ward, M., Adams, J., Stolshek, B., Kallich, J., Saag, G., Patterns of Osteoporosis Treatment Change in a Medicare Advantage Prescription Drug (MAPD) Plan. *Journal of Managed Care Pharmacy*, 17:265-266, 2011

- Song, X., Shi, N., Badamgarav, E., Kallich, J., Varker, H., Lenhart, G., Curtis, J., Cost Burden of Second Fracture in the US Health System. *Bone*, 48:828–836, 2011.
- Polsky, D., Eremina, D., Hess, G., Hill, J., Hulnick, S., Roumm, A., Whyte, J., Kallich, J., The Importance of Clinical Variables in Comparative Analyses Using Propensity Score Matching: the Case of ESA Costs for the Treatment for Chemotherapy Induced Anemia. *Pharmacoeconomics*, 29:755-765, 2009.
- Song, X., Long, S., Marder, W., Sullivan, S., Kallich, J., The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa. *Annals of Pharmacotherapy*, 43:1203-1210, 2009.
- Daniel, D., Hurley, D., Whyte, J., Willey, V., Wilson, M., Kallich, J., Use and Cost of Erythropoiesis-stimulating Agents in Patients with Cancer. *Curr Med Res Opin*, 25:1775-1784, 2009.
- Cella, D., Viswanathan, H., Hays, R., Mendoza, T., Stein, D., Pasta, D., Foreman, R., Vadhan-Raj, V., Kallich, J., Development of a Fatigue and Functional Impact Scale (FFIS) for Use in Anemic Cancer Patients Receiving Chemotherapy. *Cancer*, 113:1480-1488, 2008.
- Rubin, R., Glaspy, J., Adams, J., Mafilios, M., Wang, S., Viswanathan, H., Kallich, J., Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks Versus Epoetin Alfa Every Week for the Treatment of Chemotherapy-induced Anemia from a US Payer's Perspective. *Journal of Medical Economics*, 11:199–213, 2008.
- Berger, A., Edelsberg, J., Kallich, J., Oster, G., Use of Darbepoetin Alfa and Epoetin Alfa for Cancer-Related Anemia in Clinical Practice. *Clinical Therapeutics*, 30:1-13, 2008.
- Turner, R., Quittner, A., Parasuraman, B., Kallich, J., Cleeland, C., Patient-Reported Outcomes: Instrument Development and Selection Issues. *Value in Health*, 10:S86–S93, 2007.
- Churchill, D., Macarios, D., Attard, C., Kallich, J., Goeree, R., Costs Associated with Erythropoiesis Stimulating Agent (ESA) Administration to Hemodialysis Patients. *Nephron Clinical Practice*, 106:193-198, 2007.
- Houts, A., Loh, G., Fortner, B., Kallich, J., Patient and Caregiver Time Burden Associated with Anaemia Treatment in Different Patient Populations. *Supportive Care in Cancer*, 14:1195-1204, 2006.
- Meehan, K., Tchekmedyian, N., Smith, R., Kallich, J., Resource Utilization and Time Commitment Associated with Correction of Anemia in Cancer Patients Using Epoetin Alfa. *Clinical Drug Investigation*, 26:593-601, 2006.
- Littlewood, T., Kallich, J., San Miguel, J., Hendricks, L., Hedenus, M., Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anaemic Patients with Lymphoproliferative Malignancies. *Journal of Pain and Symptom Management*, 31:317-325, 2006.
- Kallich, J., McDermott, A., Xu, X., Fayers, P., Cella, D., The Relationship Between Patient Knowledge of Hemoglobin Levels and Health-Related Quality of Life. *Quality of Life Research*, 15:57-68, 2006.
- Berndt, E., Kallich, J., McDermott, A., Xu, X., Lee, H., Glaspy, J., Reductions in Anaemia and Fatigue Are Associated with Improvements in Productivity. *Pharmacoeconomics*, 23:505-514, 2005.
- Lyman, G., Berndt, E., Kallich, J., Erder, M., Crown, W., Long, S., Lee, H., Finkelstein, S., The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. *Value in Health*, 8:149-156, 2005.
- Berndt, E., Crown, W., Kallich, J., Lyman, G., Long, S., The Impact of Anemia and Its Treatments on Employee Disability and Medical Costs. *Pharmacoeconomics*, 23:183-192, 2005.
- Cella, D., Kallich, J., McDermott, A., Xu, X., The Longitudinal Relationship of Hemoglobin, Fatigue and Quality of Life in Anemic Cancer Patients: Results from Five Randomized Clinical Trials. *Annals of Oncology*, 15:979-986, 2004.
- Smith, R., Glaspy, J., Tchekmedyian, S., Austin, M., Kallich, J., Hemoglobin Increase Is Associated with Improved Health-Related Quality of Life in Patients with Cancer Who Are Not Receiving Chemotherapy. *Supportive Cancer Therapy*, 1:49-54, 2003.
- Tchekmedyian, S., Kallich, J., McDermott, A., Fayers, P., Erder, M., The Relationship Between Psychologic Distress and Cancer-Related Fatigue. *Cancer*, 98:198-203, 2003.

- Kallich, J., Tchekmedyian, S., Damiano, A., Shi, J., Black, J., Erder, M.E., Psychological Outcomes Associated with Anemia-Related Fatigue in Cancer Patients. *Oncology*, 16 (9), 117-124, 2002.
- Revicki, D., Gold, K., Buckman, D., Chan, K., Kallich, J., Woolley, J. Imputing Health Status Scores Missing Due to Mortality: Results of a Simulation Comparing Multiple Techniques. *Medical Care*, 39:61-71, 2001.
- Rao, S., Carter, W., Mapes, D., Kallich, J., Kamberg, C., Spritzer, K., Hays, R. Development of Subscales from the Symptom/Problems and Effects of Kidney-Disease Items in the Kidney Disease Quality of Life (KDQOL) Instrument,. *Clinical Therapeutics*, 22: 1099-1111, 2000.
- Zwanziger, J., Kravitz, R., Hosek, S., Hart, K., Sloss, E., Sullivan, O., Kallich, J., Goldman, D. Providing Managed Care Options for a Large Population: Evaluating the CHAMPUS Reform Initiative. Civilian Health and Medical Program of the Uniformed Services. *Military Medicine*, 165:403-10, 2000.
- Meehan, K., Matias, C., Rathore, S., Sandler, S., Kallich, J., Labrecque, J., Erder, M., Schulman, K., Platelet Transfusions: Utilization and Associated Costs in a Tertiary Care Hospital. *American Journal of Hematology*, 64:251-6, 2000.
- Brocco, S., Kallich, J., Adams, J., Silberner, J., Organ Transplantation Research Initiatives in New Jersey. *New Jersey Medicine*, 94:61-62, 1997.
- Edgell, E., Coons, S., Carter, W., Kallich, J., Mapes, D., Damush, T., Hays, R., A Review of Health Related Quality of Life Measures Used in End-Stage Renal Disease. *Clinical Therapeutics*, 18:887-937, 1996.
- Farley, D., Carter, G., Kallich, J., Lucas, T. Modified Capitation and Treatment Incentives for End Stage Renal Disease. *Health Care Financing Review*, 17:129-142, 1996.
- Kanouse, D., Kallich, J., Kahan, J., Dissemination of Practice-Relevant Information to Health Care Providers and Payers. *Health Policy*, 34:167-192, 1995.
- Hays, R., Kallich, J., Mapes, D., Coons, S., Carter, W., Development of the Kidney Disease Quality of Life (KDQOL) Instrument. *Quality of Life Research*, 3:329-338, 1994.
- Kallich, J. and Hays, R., The Benefits and Pitfalls of Proprietary Health Services Research. *Quality of Life Research*, 3:231-233, 1994.
- Barton, P. and Kallich, J., The Allocation of Kidneys for Transplantation: U.S. Distribution Models for Cadaveric Renal Organs. *Transplantation Proceedings*, 26:3685-3692, 1994.
- Kallich, J. and Merz, J., The Transplant Imperative, Protecting Living Donors from the Pressure to Donate. *Journal of Corporation Law*, 20:139-154, 1994.

Book Chapters

- Kallich, J., Wyant, T., Krushat, M., The Effect of DR Antigens, Race, Sex, and Peak PRA on Estimated Median Waiting Time for a First Cadaver Kidney Transplant. *Clinical Transplants*, Edited by P. Terasaki, Los Angeles: University of California Los Angeles, 1990.
- Miller, J. and Kallich, J., Is There Still a Small Town Culture in America? *The Small City and Regional Community*, Vol. 2. Edited by E. Miller and R. Wolinsky, Stevens Point: University of Wisconsin Foundation Press, 1979.

Letters

- Song, X., Long, S., Marder, W., Sullivan, S., Kallich, J., Reply: The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa. *Annals of Pharmacotherapy*, 44: 595-596, 2010.

Policy Papers, Program Reports and Major Consultancy Reports

- Kallich, J., Adams, J., Silberner, J., Final Report: An Assessment of Solid Organization Transplantation Services In New Jersey. Health Policy Analysis, 1995.

- Bower, A., Carter, G., Kallich, J., Brown, J., Data Collection Protocol and Instruments for a Cost Analysis of Hemodialysis Treatments. RAND, DRU-770-HCFA, 1995.
- Kallich, J., Mittman, B., Weidmer, B., Oken, C., Summary and Analysis of Existing Guidelines and Review Criteria Relating to Prediction and Prevention of Pressure Ulcers in Adults, RAND, PM-235-AHCPR, 1994.
- Kallich, J. and Bentow, S., Ancillary Outpatient Billings for ESRD Beneficiaries, RAND, DRU-562-HCFA, 1994.
- Kallich, J., Markovich, M., Litwin, M., Vascular Access Procedures for End-Stage Renal Disease Medicare Beneficiaries. RAND, DRU-420-HCFA 1993.
- Bower, A., Kallich, J., Carter, G., Design for a Cost-Effectiveness Protocol for the NIH Hemodialysis Study, RAND, 1993.
- Farley, D., Kallich, J., Carter, M., Lucas, T., Spritzer, K., Designing a Capitation Payment Plan for Medicare ESRD Services. RAND, MR-518-HCFA, 1993.
- Kallich, J., Adams, J., Lindsey-Barton, P., Access to Cadaveric Kidney Transplantation. RAND, MR-202-HCFA, 1993.
- Kallich, J., Adams, J., Rahman, A., Patterns of Inpatient Physician Billings for Patients with End Stage Renal Disease. RAND, MR-131, 1992.
- Farley, D., Kallich, J., Neu, C., Abrahams, A., Measurement of Services Provided by Physicians under the Monthly Capitation Payment: A Proposed Study Design. National Technical Information Service, PB93-112738/XAB, 1991.
- Greenleaf, J., and Kallich, J., Evaluation of the Comprehensive Perinatal Care Program. Office of the Inspector General, DHHS, OEI-0632, August 1990.
- Kallich, J., Yessian, M., Wyant, T., Krushat, M., The Distribution of Organs for Transplantation: Expectations and Practices. Office of the Inspector General, DHHS, OAI-0550, June 1990.
- Luehers, J., Huskamp, H., Kallich, J., Establishing a Comprehensive Health Insurance Program: The Experience in Massachusetts. *Capital Ideas*, 9:1-7, 1988.
- Kallich, J., Chapter 23, An Act to Make Health Security Available to All Citizens of the Commonwealth and to Improve Hospital Financing, A Summary. Massachusetts Executive Office of Human Services, 1988.
- Kallich, J., Kattler, D., Boland, J., Massachusetts Statistics for Medical Assistance - Fiscal Year 1985, Massachusetts Department of Public Welfare, 1986.
- Anderka, M., Brown, L., Kallich, J., Evans, F., The Health of Women and Children in Massachusetts, Massachusetts Department of Public Health, 1986.
- Evans, F. and Kallich, J., The Epidemiology of Infant Mortality, Low Birthweight, and Utilization of Prenatal Care in Massachusetts, Massachusetts Department of Public Health, 1984.
- Kallich, J., Diethylstilbestrol (DES) Clinic Program Report. Massachusetts Department of Public Health, 1983.
- Massachusetts Labor Research Group, *A Critique of the Cooper-Lybrand Reasonable Expectancies*. Consultant report prepared for Local 509, Service Employees International Union, Boston, Massachusetts, 1979.

Abstracts

- Quach, D., Liede, A., Byekwaso, S., Eremina, D., Kossar, B., Zhou, L., Quigley, J., Kallich, J., Adams, J., Smith, P., Projection Methods Using Oncology Electronic Health Records to Produce Nationally Representative Estimates, *Pharmacoepidemiology and Drug Safety*, in press.
- Gastanaga, V., Lethen, J., Vanderwalde, A., Cyprien, L., Kelsh, L., Kallich, J., Treatment patterns in patients with early and advanced malignant melanoma. *Journal of Clinical Oncology*, in press.

- Ward, M., Viswanathan, H., Xu, Y., Adams, J., Stolshek, B., Kallich, J., Saag, K., Association between osteoporosis treatment change and total direct healthcare costs in Medicare Advantage Prescription Drug (MAPD) plan. *Journal of Managed Care Pharmacy*, 17:552, 2011.
- Nordstrom, B., Whyte, J., Kallich, J., Development of Algorithms to Identify Metastatic Cancer in Claims Data Using Oncology EMR Data, Methods Symposium for Developing and Analyzing Clinically Rich Data for Patient-Centered Outcomes Research (PCOR), *Agency for Health Research and Quality*, 2011.
- Whyte, J. L., Engel-Nitz, N., Teitelbaum, A., Gomez-Rey, G., Kallich, J., A Validation Study of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data. *Value in Health*, 14:A6, 2011.
- Chastek, B., Harley, C., Kallich, J., Newcomer, L., Paoli, C., Teitelbaum, A., Costs and utilization of oncology health services at the end of life, *Journal of Clinical Oncology*, 29:400s, 2011.
- Cai, Q., Curtis, J., Wade, S., Viswanathan, H., White, J., Balasubramanian, A., Kallich, J., Adams, J., Stolshek, B., Medication Adherence in Patients on Osteoporosis Therapy: Physician Perceptions Versus Patient Behavior, *ASBMR*, 2011.
- Xu, Y., Viswanathan, H., Ward, A., Adams, J., Stolshek, B., Kallich, J., Saag, K. Patterns of Osteoporosis Treatment Change in a Medicare Advantage Prescription Drug (MAPD) Plan, *American Journal of Managed Care Pharmacy*, 2011.
- Xu, Y., Ward, M., Viswanathan, H., Adams, J., Stolshek, B., Clay, R., Kallich, J., Saag, K., Associations between osteoporosis treatment change, adherence, and incident fractures among members in a Medicare Advantage Prescription Drug (MAPD) plan. *J Bone Miner Res*. 26:S506-507, 2011.
- Fisher, M., Cai, Q., Paoli, C., Lyons, A., Wasser, T., Rodriguez, R., White, S., Kallich, J., Barron, J., Brawley, O., Racial Disparities in African-American vs. White Women with Newly Diagnosed Breast Cancer in a Southeast United States Health Plan, *Value in Health*, 2011.
- Wade, S., Curtis, J., Yu, J., White, J., Stolshek, B., Merinar, C., Balasubramanian, A., Kallich, J., Adams, J., Viswanathan, H., Medication Adherence and Fracture Risk Among Patients Using Osteoporosis Medications in a Large U.S. Health Plan, *Bone*, 2011.
- Viswanathan, H., White, J., Wade, S., Yu, J., Curtis, J., Stolshek, B., Merinar, C., Kallich, J., Balasubramanian, A., Adams, J., Incremental Cost of Osteoporosis-related Fractures in a Large U.S. Managed Care Population, *Bone*, 2010.
- Viswanathan, H., Wade, S., Curtis, J., Yu, J., White, J., Stolshek, B., Merinar, C., Balasubramanian, A., Kallich, J., Adams, J., Osteoporosis Medication Adherence and Fracture Risk Among Women in a Large U.S. Health Plan, *Arthritis & Rheumatism*, 2010.
- Viswanathan, H., White, J., Wade, S., Yu, J., Curtis, J., Stolshek, B., Merinar, C., Kallich, J., Balasubramanian, A., Adams, J., Assessment of the Incremental Cost of Osteoporosis-related Fractures Among Women in a Large U.S. Managed Care Population, *Arthritis & Rheumatism*, 2010.
- Shi, N., Song, X., Badamgarav, E., Kallich, J., Varker, H., Lenhart, G., Curtis, J., Cost burden of second fracture in patients with commercial insurance. *Value in Health*, 13: A124, 2010.
- Song, X., Long, S., Marder, W., Sullivan, S., Kallich, J., The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa. *Blood*, 112:469, 2008.
- Hess, G., Hulnick, S., Whyte, J., Kallich, J., Erythropoiesis Stimulating Agent Patterns in Electronic Medical Records of Cancer Patients. *J Oncology Pharmacy Practice*, 13:168, 2007.
- Naeim, A., Friedman, L., Elkin, E., Adams, J., Viswanathan, H., Kallich, J., Glaspy, J., Patterns of Care in Patients with Chemotherapy Receiving Erythropoiesis Stimulating Agents (ESAs). *Blood*, 110:964A, 2007.
- Whitlock, K., Friedman, L., Naeim, A., Pasta, D., Elkin, E., Viswanathan, H., Kallich, J., Glaspy, J., Adherence to Anemia Treatment Guidelines in US Community Oncology Practices. *Hematology/Oncology Pharmacy Association*, 2007.

- Daniel, G., Hurley, D., Whyte, J., Grochulski, W., Willey, V., Kallich, J., Differences in Erythropoietin Stimulating Agent Dose and Use in Cancer Patients. *Supportive Care in Cancer*, 15:758, 2007.
- Friedman, L., Engelking, C., Harvey, C., Wickham, R., Miller, K., Kallich, J., EDUCATE STUDY (Educating Clinicians To Achieve Treatment Guideline Effectiveness): Development And Implementation. *Oncology Nursing Forum*, 34:56, 2007.
- Friedman, L. Aksamit, I., Miller, K., Viswanathan, H., Kallich, J., Naeim, A., Glaspy, J., Ozer, H., The EDUCATE Study (Educating Clinicians to Achieve Treatment Guideline Effectiveness): Design and Methods. *Supportive Care in Cancer*, 15:785, 2007.
- Rubin, R., Glaspy, J., Adams, J., Mafilios, M., Scharf, J., Viswanathan, H., Kallich, J., Cost-minimization Analysis of Darbepoetin Alfa Every Three Weeks Versus Weekly Epoetin Alfa Initiated at Labeled Starting Doses for the Treatment of Chemotherapy-induced Anemia. *Am J Health-Syst Pharm*, 63:20, 2006.
- Henry, D., Viswanathan, H., Wade, S., Servin, M., Kallich, J., The Patient Experience of Fatigue: A Cross-Sectional Study of Cancer Patients. *Blood*, 108:958a, 2006.
- Song, X., Long, S, Kallich, J., Marder, W., Impact of Clinical/Demographic Characteristics and Duration of Clinical Benefit on Average Weekly Doses of Darbepoetin Alfa and Epoetin Alfa in Oncology: Results from a Claims Analysis. *Blood*, 108:482b, 2006.
- Berger, A., Kallich, J., Oster, G., Use of Darbepoetin Alfa and Epoetin Alfa for Cancer-Related Anemia in Clinical Practice. *Support Care Cancer*, 14:592; 2006.
- Cella, D., Viswanathan, H., Hays, R., Medoza, T., Stein, K., Pasta, D., Potter, L., Vadhan-Raj, S., Kallich, J., Development of the Functional Capacity Screening Tool (FCST): A Brief Instrument to Identify Functional Capacity Deficits in Anaemic Cancer Patients. *Journal of Clinical Oncology*, 24:491, 2006.
- Berger, A., Kallich, J., Oster, G., Darbepoetin Alfa and Epoetin Alfa for Cancer-Related Anemia in Clinical Practice. *Journal of Clinical Oncology*, 23:7592, 2006.
- Cella, D., Evans, W., Wallace, J., Kallich, J., Blayney, D., and Vadhan-Raj, S., The Relationships Between FACT-Fatigue Scores and Physical Function in Patients with Chemotherapy Induced Anemia Treated with Darbepoetin Alfa. *Supportive Care in Cancer*, 14:592, 2004.
- Syrjala, K., Hays, R., Kallich, J., Farivar, S., Abrams, J., Erder, M., Impact of Oral Mucositis and Its Sequelae on Quality of Life. *Blood*, 2003.
- Isitt, J., Glaspy, J., Tchekmedyian, N., Erder, M., Kallich, J., Front Loaded Darbepoetin Alfa Provides Quicker and Sustained Improvement in Patient Reported Outcomes Compared to Epoetin Alfa. *Quality of Life Research*, 7:1412, 2003.
- Kallich, J., Xu, X., McDermott, A., Erder, M., Cella, D., Reducing Anemia Related Fatigue Improves Health Related Quality of Life in Anemic Cancer Patients: Results from Five Randomized Clinical Trials. *Quality of Life Research*, 7:1581, 2003.
- Glaspy, J., Meehan, K., Lu, Z., Ansari, R., Brow, R., Erde, M., Kallich, J., Lee, H., Lyman, G., A Model to Estimate the Provider Cost Savings of Switching to Long Acting Cytokines for Anemia and Neutropenia in Patients Undergoing Chemotherapy Treatment. *Blood*, 100:502b, 2002.
- Meehan, K., Tchekmedyian, S., Smith, R., Kleinman, L., Fitzmaurice, T., Kallich, J., An Activity Based Costing Estimate of Anemia Correction Activities in an Oncology Practice. *Blood*, 100:502b, 2002.
- Berndt, E., Kallich, J. Xu, X., Erder, E., Lee, H., Glaspy, J., Reductions in Anemia and Fatigue are Associated with Improvements in Productivity. *Blood*, 100:876a, 2002.
- Smith, R., Glaspy, J., Austin, M., Kallich, J., Patients with Anemia of Cancer and No Chemotherapy Show Improvement in Health-related Quality of Life (HRQOL) When Hemoglobin Improves. *Blood*, 100:877a, 2002.

- Kallich, J., Erder, M., Glaspy, J., Tchekmedyian, S., Improvements in Fatigue and Physical Well Being Appear to Be Higher in Patients Receiving Darbepoetin Alfa than Patients Receiving Epoetin Alfa. *Supportive Care in Cancer*, 10:366, 2002.
- Finkelstein, S., Berdt, E., Crown, W., Kallich, J., Erder, H., Lyman, G., Anemia as a Predictor of High Cost in Recently Diagnosed Patients with Cancer. *Supportive Care in Cancer*, 10:365, 2002.
- Berd, E., Crown, B., Finkelstein, S., Kallich, J., Erder, H., Lyman, G., Anemia in Employed Patients with Cancer Affects Absenteeism From Work. *Supportive Care in Cancer*, 10:366, 2002.
- Churchill, D., Goeree, R., Macarios, D., Attard, C., Kallich, J., Costs of Epoetin Alfa (Eprex) Administration to Hemodialysis (HD) Patients (PTS): A Canadian Time and Motion Study. *Journal of American Society of Nephrology*, 13:220A, 2002.
- Kallich, J., Erder, M., Glaspy, J., Tchekmedyian, S. Darbepoetin Alfa Has Higher Observed Improvements in Fatigue and Physical Well Being Than Epoetin Alfa. *European Hematology Journal*, 3:86, 2002.
- Tchekmedyian, S., Kallich, J., Shi, J., Cella, D., Erder, M., Pirker, E., Depression Scores of Anemic Patients with Cancer Improve when Hemoglobin Improves. *European Hematology Journal*, 3:86, 2002.
- Kallich, J., Erder, M., Glaspy, J., Tchekmedyian, S., Loading Dose of Darbepoetin Alfa Results in Greater Observed Improvements in Fatigue and Physical Well-being than Standard Treatment. *American Society of Clinical Oncology Proceedings*, 21: 1466, 2002.
- Kallich, J., Erder, H., Rossi, G., Poulsen, E., Colowick, A., Isitt, J., Improvement in Hemoglobin Levels Reduces Fatigue and Improves Health Related Quality of Life (HRQOL) of Anemic Cancer Patients. *Quality of Life Research*, 10:229, 2001.
- Kallich, J., Erder, M., Glaspy, J., Vansteenkiste, J., Rossi, G., Poulsen, E., Improvement in Haemoglobin Levels Improves Health-Related Quality of Life (HRQOL) of Anaemic Cancer Patients. *European Journal of Cancer*, 37:441, 2001.
- Kallich, J., Erder, M., Glaspy, J., Vansteenkiste, J., Rossi, G., Poulsen, E., Improvement in Haemoglobin Levels Improves Health-Related Quality of Life (HRQOL) of Anaemic Cancer Patients. *The Hematology Journal*, 1:185, 2001.
- Kallich, J., Himmelberger, D., Linguistic Validation of a Daily Quality of Life Questionnaire for Multinational Clinical Trials. *Quality of Life Research*, 6:657, 1997.
- Woolley, J., Bayliss, M., Kallich, J., Adams, J., Erder, M., Optimal Assessment of HRQOL: An Empirical Analysis of Survey Timing and Summary Measures. *Quality of Life Research*, 6:745, 1997.
- Revicki, D., Gold, K., Kallich, J., Woolley, J., Imputing Health Status Scores Missing due to Mortality: Comparison of Multiple Techniques. *Quality of Life Research*, 6:708, 1997.
- Kallich, J., Erder, M., LaBrecque, J. Throop, D., Joyce, A., Tucker, A., Berberian, L., Gordon, G., Inpatient Platelet Use and Costs for Patients with Solid Tumors: A Comparison Between Refractory and Non-Refractory Patients. *Blood* 89:775a, 1997.
- Kallich, J., Erder, H., LaBrecque, J. Throop, D., Joyce, A., Tucker, A., Berberian, L., Gordon, G., Inpatient Platelet Use and Costs for Patients with Hematological Diseases: A Comparison Between Refractory and Non-Refractory Patients. *Blood* 88:334a, 1996.
- Snider, C., Erder, H., LaBrecque, J., Kallich, J., Calhoun, L., Petz, L., Lill, M., What Are the True Costs of Platelet Transfusions? A Prospective Time and Motion Study of Resources Used for Platelet Transfusions at UCLA Medical Center. *Blood* 88:333a, 1996.
- Kallich, J. Adapting ESRD Therapy to Capitated Health Care. *1994 Contemporary Issues in Hemodialysis Symposium*, 1994.